山东省全民体育健身条例
山东省人大常委会
山东省全民体育健身条例
2004年9月23日山东省第十届人民代表大会常务委员会第十次会议通过
第一章 总 则
第一条 为了促进全民体育健身活动的开展，增强公民体质，维护公民参加体育健身活动的合法权益，根据《中华人民共和国体育法》等法律、法规，结合本省实际，制定本条例。
第二条 本省行政区域内公共体育健身设施的规划、建设、使用、维护和全民体育健身活动的组织、开展、指导和管理，适用本条例。
本条例所称公共体育健身设施，是指由各级人民政府或者社会力量建设和举办的，向公众开放用于开展体育健身活动的公益性的体育健身场（馆）、中心、场地、设备（器材）。
第三条 开展全民体育健身活动应当遵循因地制宜、形式多样、注重实效和科学文明的原则。
第四条 县级以上人民政府体育行政部门主管本行政区域内的全民体育健身工作。
县级以上人民政府有关部门按照各自职责，做好全民体育健身工作。
街道办事处、乡（镇）人民政府应当明确有关机构和人员负责全民体育健身工作，积极组织符合基层特点的全民体育健身活动。
第五条 工会等社会团体应当结合工作特点，积极组织开展全民体育健身活动。
各类社会体育组织应当按照社会团体管理规定和章程，积极组织开展体育健身活动。
鼓励社会力量组织开展全民体育健身活动。
第六条 各级人民政府应当将全民体育健身工作纳入国民经济和社会发展计划，将开展全民体育健身工作所需经费、公共体育健身设施建设费用列入财政预算和基本建设投资计划，并随着国民经济的发展和财政收入的增长逐步增加。
全民体育健身经费和公共体育健身设施建设费用必须全部用于全民体育健身工作。
第七条 各级人民政府及其有关部门应当对在全民体育健身工作中做出显著成绩的单位和个人给予表彰和奖励。
第八条 每年五月为本省全民体育健身月。
第二章 健身设施
第九条 各级人民政府应当按照国家和省对城乡公共体育设施用地定额指标的规定，将公共体育健身设施建设纳入土地利用总体规划和城乡建设规划。
县级以上人民政府体育行政部门应当根据土地利用总体规划和城乡建设规划确定的公共体育设施建设预留地，会同同级规划行政部门编制公共体育健身设施建设专业规划，报同级人民政府批准后实施。
第十条 公共体育健身设施的规划和建设应当遵循统筹规划、合理布局、规范实用和方便群众的原则。
第十一条 公共体育健身设施应当按照国家有关标准设计，符合实用
、安全、科学、美观的要求。
建设公共体育健身设施，应当充分考虑未成年人、老年人和残疾人的特殊要求，并采取无障碍措施，满足各类人群进行体育锻炼的需要。
第十二条 县级以上人民政府应当按照国家和省有关规定，结合当地实际，规划建设一定规模的公共体育健身活动中心。
街道办事处、乡（镇）人民政府驻地和有条件的村（居），应当规划建设小型多样、方便实用的体育健身场所。
企业事业单位应当结合本单位实际，建设或者配置相应的体育健身设施、器材，为职工健身锻炼提供必要的条件。
广场、公园等公共场所应当因地制宜，配套建设相应规模的体育健身设施。
第十三条 新建、改建、扩建居民住宅区，应当按照国家和省有关规定规划和建设相应的体育健身设施。体育健身设施的规划设计方案未达到国家和省有关规划技术要求的，规划行政部门不予发放建设工程规划许可证。
居民住宅区配套建设的体育健身设施，应当与居民住宅区的主体工程同时设计、同时施工、同时投入使用，组织验收时应当有当地体育行政部门参加。任何单位和个人不得擅自改变体育健身设施建设项目和功能，不得缩小建设规模和降低用地指标。
第十四条 各级人民政府应当加大对公共体育健身设施的投入，保障公民进行体育健身活动的需要。
彩票公益金应当按照国家和省规定的支出范围和比例，安排用于公共体育健身设施的建设、管理和维护。
政府投入的资金和用于公共体育健身设施的彩票公益金，应当向城市社区和农村倾斜。
第十五条 建设公共体育健身设施需要使用国有土地的，可以按照国家和省有关规定以划拨方式取得国有土地使用权。
第十六条 县级以上人民政府应当制定政策，鼓励社会力量举办面向社会的各类体育健身设施和体育健身经营场所。
鼓励向全民体育健身事业捐赠资金和设施。捐赠人依法享有税收等优惠政策。
第十七条 公共体育健身设施应当向社会开放，并在法定节假日和学校寒暑假期间延长开放时间。
鼓励机关、企业事业单位的体育健身设施向社会开放。
学校的体育健身设施应当在节假日和学校寒暑假期间向学生开放；在不影响教学和学校安全的情况下，应当向社会开放。
第十八条 政府投资兴办的公园应当对公众晨练和晚练活动免费开放。
机关、企业事业单位的体育健身设施向社会开放，可以实行有偿使用。
第十九条 公共体育健身设施向社会开放，不需要增加投入和专门服务的，应当免费开放；需要消耗水、电、气或者器材有损耗的，可以适当收费，但不得以营利为目的。收费标准由省财政、物价部门会同有关部门确定。
实行有偿使用的公共体育健身设施应当对未成年人、老年人和残疾人免费开放或者给予优惠。
第二十条 公共体育健身设施管理单位不得将设施的主体部分用于非体育活动，但因举办公益性活动或者大型文化活动等特殊情况需要临时出租的除外。临时出租时间一般不得超过十日；租用期满，租用人应当负责恢复原状，不得影响该设施的功能、用途。
第二十一条 公共体育健身设施管理单位应当在醒目位置标明设施的使用方法和注意事项。
公共体育健身设施管理单位应当建立使用、维护、修理、更新、安全、卫生等管理制度，定期对体育健身设施进行维修保养，保证正常使用。
第二十二条 公共体育健身设施管理单位的收入，应当用于公共体育健身设施的维护、管理和事业发展，不得挪作他用。
体育行政部门和有关部门应当按照政企分开、政事分开的原则，加强对公共体育健身设施经营管理的监督检查。
第二十三条 任何单位和个人不得侵占公共体育健身设施预留地或者改变其用途。
因特殊情况需要调整公共体育健身设施预留地的，应当重新确定建设预留地。重新确定的建设预留地不得少于原有面积。
第二十四条 任何单位和个人不得侵占、破坏公共体育健身设施。
任何单位和个人不得擅自拆除公共体育健身设施或者改变其功能、用途。因公共利益确需拆除公共体育健身设施或者改变其功能、用途的，应当依照有关法律、法规的规定办理批准手续。
第三章 健身活动
第二十五条 学校应当将体育作为学生素质教育的重要组成部分，按照国家规定实施学生体质健康标准，加强对学生的体质监测，提高学生身体素质。
学校应当按照国家有关规定开设体育课，并将体育课列为考核学生学业成绩的科目；组织开展广播操和多种形式的课外体育活动，保证学生在学校期间，每天有不少于一小时的体育活动时间。
学校应当每年至少举行一次全校性体育运动会。
第二十六条 居民委员会等基层组织应当结合社区特点，组织开展业余、自愿、小型、多样的体育健身活动。
村民委员会和乡（镇）基层文化体育组织应当结合农村特点，组织开展适合农民参加的各类体育健身活动。
第二十七条 机关、企业事业单位、社会团体和其他组织应当结合本单位特点，制订体育健身活动计划，组织工前或者工间体育锻炼，定期举办群众性单项体育比赛或者综合运动会，开展经常性的体育健身活动。
第二十八条 各级各类体育教育、训练机构可以利用现有的场地、设施、器材和技术人员，组织举办各种体育健身俱乐部、夏（冬）令营、培训班等，传授、推广、普及科学、实用的体育健身知识和方法。
第二十九条 各级人民政府应当通过举办城市运动会、农民运动会等竞技体育比赛，推动体育健身活动的广泛开展。
各级人民政府应当采取措施，鼓励发掘、整理民族、民间的传统体育健身项目，开展传统体育健身活动。
第三十条 鼓励支持科研机构、高等院校开展体育健身科学研究，推广科学的体育健身新项目、新器材、新方法。
广播、电视、报刊、互联网等应当设立全民体育健身专题、专栏，积极宣传推广科学、文明、健康的体育健身项目和方法。
第三十一条 公民进行体育健身活动，应当讲科学、讲文明，遵守体育健身场所的管理制度，爱护体育健身设施和环境，遵守社会公德，不得影响其他公民的正常工作和生活。
任何单位和个人不得在体育健身活动中宣传封建迷信、邪教、色情、暴力和其他不健康的内容，不得利用体育健身活动进行赌博等违法行为。
第三十二条 实行社会体育指导员技术等级制度。社会体育指导员技术等级的认定标准和程序，按照国家有关规定执行。
社会体育指导员在群众性体育活动中从事健身运动技能传授、科学健身指导和组织管理，宣传科学的体育健身知识。
从事社会体育健身指导服务的人员，应当依法取得社会体育指导员技术等级证书，并按照技术等级证书确定的范围从事社会体育健身指导服务。
体育行政部门应当加强社会体育指导员的组织和培训工作。
第三十三条 公共体育健身场所应当根据项目情况，配备社会体育指导员。
经营性体育健身场所必须配备具有相应执业资格的体育健身指导人员。
第三十四条 经营性体育健身场所应当依法设立，合理收费，提供安全、优质、科学、文明的健身服务。
第四章 法律责任
第三十五条 违反本条例规定，新建、改建、扩建居民住宅区未按照规划要求建设体育健身设施的，由规划行政部门责令建设单位限期补建；逾期未补建的，由规划行政部门依法查处。
第三十六条 违反本条例规定，侵占公共体育健身设施预留地或者改变其用途的，由土地、规划行政部门依据各自职责责令限期改正；逾期不改正的，由作出决定的机关依法申请人民法院强制执行。
第三十七条 违反本条例规定，侵占、破坏公共体育健身设施的，由体育行政部门责令限期改正，恢复原状；造成设施损坏的，应当赔偿损失；构成违反治安管理行为的，由公安机关依法给予治安处罚；构成犯罪的，依法追究刑事责任。
第三十八条 违反本条例规定，在体育健身活动中宣扬封建迷信、邪教、色情和暴力，或者利用体育健身活动进行赌博等违法行为，构成违反治安管理行为的，由公安机关责令立即停止违法行为，并依法给予治安处罚；构成犯罪的，依法追究刑事责任。
第三十九条 违反本条例规定，有下列行为之一的，由体育行政部门给予警告，责令停止违法行为，没收违法所得，处以二百元以上二千元以下的罚款；情节严重的，处以二千元以上二万元以下的罚款：
（一）未取得社会体育指导员技术等级证书从事经营性社会体育健身指导的；
（二）社会体育指导员超出技术等级证书规定范围从事经营性社会体育健身指导的；
（三）社会体育指导员在社会体育指导活动中以欺诈手段牟取利益的。
第四十条 体育、教育、规划、土地、建设等行政部门及其工作人员违反本条例规定，不依法履行法定职责，或者滥用职权、谋取私利的，对负有责任的主管人员和其他直接责任人员，依法给予行政处分；构成犯罪的，依法追究刑事责任。
第五章 附 则
第四十一条 本条例自2004年11月1日起施行。
Provisions for Supervision of Drug Distribution
Commissioner of SFDA
Provisions for Supervision of Drug Distribution
(SFDA Decree No.26)
The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.
Shao Mingli
Commissioner of SFDA
January 31, 2007
Provisions for Supervision of Drug Distribution
Chapter I
Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.
Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.
Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.
Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.
Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.
Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors
Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.
Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.
Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.
Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.
Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.
Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.
Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.
Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.
Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.
Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.
The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.
Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.
Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.
Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.
Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.
Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.
A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.
Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.
Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.
Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.
When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.
Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.
Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.
Article 22 Any illegal purchase of drugs is prohibited.
Chapter III Supervision on Drug Purchase and Storage by Medical Institutions
Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.
Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.
Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.
Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.
Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.
A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.
Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.
Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.
Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.
Chapter IV Legal Liabilities
Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.
Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.
Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.
Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments，shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.
Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.
Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.
Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.
Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.
Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.
Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.
Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.
Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.
Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.
Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.
Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.
Chapter V Supplementary Provisions
Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.
Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.
Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.
